Pay in 4 interest-free payments of $6.64 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
In all, participants who received tirzepatide Eli Lillys (NYSE:LLY) tirzepatide achieved up to 15.7% weight loss in the SURMOUNT-2 study, sparking a potential tirzepatide versus semaglutide competition in the obesity and type 2 diabetes treatment markets
Phase 3 ( TRIUMPH)
Emerging drugs like Retatrutide and CagriSema promise greater efficacy
This dual action often leads to greater appetite reduction and improved blood sugar control
3 Anti-inflammatory effects of GLP-1 in CADinsights from human studies Study performed by Yang, et al
US$ 24.39
US$ 22.20
US$ 26.04
US$ 28.94
US$ 23.86
